Annual Report

The report highlights positive clinical readouts from three Phase 1/2 programs and continued progress across the antibody pipeline. It reports 2023 group net sales of SEK 71,461 thousand and 111 year-end employees. Sustainability disclosures describe the launch of two initiatives, including Nasdaq ESG Transparency Partner status, and work toward integrating sustainability into business strategy.